Kindred Biosciences Announces Second Quarter 2014 Financial Results

San Francisco, CA (August 13, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended June 30, 2014.

Conference Call and Webcast at 4:30 p.m. Eastern / 1.30 p.m. Pacific

“It is an exciting time for KindredBio as we develop our broad portfolio of drug candidates,” stated Richard Chin, M.D., President and Chief Executive Officer of KindredBio. “We currently anticipate the topline results from our pivotal study of CereKin shortly. The fact that we completed the entire study from start to finish in only 12 months, and on budget, is a testament to the quality and dedication of our team. As an organization, we continue to make top-notch science, patient benefit, and execution our top priorities.”

Read more

KindredBio Schedules Release of 2014 Second Quarter Financial Results and Provides Timeline for Release of CereKin Pivotal Study Data

SAN FRANCISCO, California. (Aug 6, 2014) – Kindred Biosciences, Inc. (KindredBio, NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced the date for release of its 2014 second quarter financial results and provided the timeline for the release of topline data from its multi-center, pivotal clinical trial of CereKin™ for the treatment of osteoarthritis in dogs. The Company will release its 2014 second quarter financial results on August 13, 2014 after market close. The Company is on track to lock the database for the CereKin pivotal study in the first half of August and anticipates reporting the topline study data results during the week of August 18, 2014.

Read more

KindredBio to Host Investor Breakfast on June 13 in New York City

SAN FRANCISCO, California. (June 11, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will host an Investor Breakfast on Friday, June 13, 2014 in New York City. KindredBio’s executive management team will provide an overview of the Company’s strategies and Stephen Sundlof, D.V.M, Ph.D., will offer insights into the animal health business from an FDA perspective.

Read more

KindredBio to Present at Craig-Hallum, Stifel, and Jefferies Conferences

SAN FRANCISCO, California. (May 21, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will participate in the 11th Annual Craig-Hallum Institutional Investor Conference in Minneapolis on May 28th. KindredBio will present at the Stifel Dental and Veterinary Conference on May 28th and the Jefferies Global Healthcare Conference on June 2nd, both in New York City. Details for the presentations are below:

Read more

Kindred Biosciences Announces First Quarter 2014 Financial Results and Completion of Enrollment in CereKin Pivotal Study

San Francisco, CA (May 12, 2014) Kindred Biosciences, Inc. (NASDAQ: KIN) today announced financial results for the quarter ended March 31, 2014. In addition, KindredBio announced that it has completed enrollment in KB010, its pivotal study for CereKinTM (diacerein).

Read more

KindredBio to Announce First Quarter 2014 Financial Results on Monday, May 12th

Company to Hold Conference Call and Webcast at 4:30 p.m. Eastern Time that Day

SAN FRANCISCO, California. (May 6, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, announced today that it will release its first quarter 2014 financial results on May 12, 2014 after the market close. The Company will host a conference call at 4:30 p.m. Eastern Time that day.

Read more

KindredBio Announces Closing of Public Offering and Exercise of Over-Allotment Option

SAN FRANCISCO, California. (April 8, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the closing of its public offering of 3,450,000 shares of its common stock, including 450,000 shares sold pursuant to the exercise in full by the underwriters of their over-allotment option, at a public offering price of $18.00 per share. KindredBio estimates net proceeds from the offering to be approximately $58.1 million, after deducting underwriting discounts and commissions and estimated offering expenses.

Read more

KindredBio to Present at Needham 13th Annual Healthcare Conference

SAN FRANCISCO, California. (April 4, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced that it will present at Needham 13th Annual Healthcare Conference in New York City:

Read more

Kindred Bio Announces Pricing of Public Offering

SAN FRANCISCO, California. (April 3, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its public offering of 3,000,000 shares of its common stock at a public offering price of $18.00 per share, for a total offering amount of $54,000,000 before deducting underwriting discounts and commissions and estimated offering expenses payable by KindredBio, upsized from the previously announced public offering of $50,000,000. KindredBio has granted to the underwriters a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price. All of the shares are being offered by KindredBio.

Read more

KindredBio and X-Body Announce an Exclusive Collaboration for Discovery of Antibodies for Companion Animal Health

SAN FRANCISCO, CA and WALTHAM, MA, USA. (March 31, 2014) – Kindred Biosciences, Inc. (NASDAQ: KIN) and X-Body Biosciences (X-Body) jointly announced today an exclusive alliance in which X-Body will discover fully canine, feline, and equine antibodies for companion animal health, and KindredBio will develop and commercialize these antibodies. KindredBio will provide an upfront payment, research funding, milestones, and royalties, and X-Body will exclusively license these antibodies to KindredBio.

Read more